Schedule 13D ownership disclosure
Vera Therapeutics Inc
Class A Common Stock, $0.001 par value · CUSIP: 92337R101
Event date: 2025-12-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sofinnova Venture Partners X, L.P. ("SVP X")Reported CIK 0001680200
Shares: 2,793,987.00 · Class: 3.9%
- Sofinnova Management X, L.P. ("SM X LP")
Shares: 2,793,987.00 · Class: 3.9%
- Sofinnova Management X-A, L.L.C. ("SM X LLC")
Shares: 2,793,987.00 · Class: 3.9%
- Dr. James I. Healy ("Healy")
Shares: 2,793,987.00 · Class: 3.9%
- Dr. Maha Katabi ("Katabi")
Shares: 2,847,837.00 · Class: 4.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-023756
- Form type
- SCHEDULE 13D/A
- Filer
- Sofinnova Venture Partners X, L.P.
- CIK
- CIK 1680200
- Filed
- Mar 05, 2026
- Reporting period
- Dec 10, 2025
- Description
- Schedule 13D beneficial ownership